

# **Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/AA8BCC7D1E5BEN.html>

Date: March 2022

Pages: 186

Price: US\$ 2,000.00 (Single User License)

ID: AA8BCC7D1E5BEN

## **Abstracts**

Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 15, 10, 1, 32, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).

The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Alopecia - Overview
- Alopecia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Alopecia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Alopecia - Companies Involved in Therapeutics Development
- 3SBio Inc
- Aclaris Therapeutics Inc
- Addpharma Inc
- Akaal Pharma Pty Ltd
- Alexion Pharmaceuticals Inc
- Almirall SA
- AnaptysBio Inc
- Aneira Pharma Inc
- AnToIRx Inc
- Applied Biology Inc
- Berg LLC
- Biolab Sanus Farmaceutica Ltda
- BiologicsMD Inc
- Bioquark Inc
- BirchBioMed Inc
- Caregen Co Ltd
- Chong Kun Dang Pharmaceutical Corp
- CK Regeon Inc
- Concert Pharmaceuticals Inc
- Cosmo Pharmaceuticals NV
- Dermaliq Therapeutics Inc
- dNovo Inc

Eli Lilly and Co  
Energenisis Biomedical Co Ltd  
Equillium Inc  
Exicure Inc  
Follica Inc  
HapInscience Inc  
HCell Inc  
HCW Biologics Inc  
Hope Medicine Inc  
Horizon Therapeutics Plc  
Inventage Lab Inc  
Japan Tobacco Inc  
Jiangsu Hengrui Medicine Co Ltd  
JN Biosciences LLC  
Johnson & Johnson  
JW Pharmaceutical Corp  
Kedi Biomedical Co Ltd  
Kintor Pharmaceutical Ltd  
Kuhnle Pharmaceutical Co Ltd  
LG Chem Ltd  
Maxinovel Pharmaceuticals  
METiS Pharmaceuticals  
Mirae Cell Bio Co Ltd  
Nepsone ehf  
OliX Pharmaceuticals Inc  
Omega Therapeutics Inc  
OnQuality Pharmaceuticals LLC  
Pfizer Inc  
Phio Pharmaceuticals Corp  
Ponce Therapeutics Inc  
ProTransit Nanotherapy LLC  
RiverTown Therapeutics Inc  
Samson Clinical Pty Ltd  
Shenzhen Chipscreen Biosciences Co Ltd  
siRNAgen Therapeutics Corp  
Sisaf Ltd  
Soterios Ltd  
Stemson Therapeutics Corp  
Suzhou Zelgen Biopharmaceutical Co Ltd

TagCyx Biotechnologies  
Technoderma Medicines Inc  
Throne Biotechnologies Inc  
Tigo GmbH  
Triple Hair Inc  
Tritech Biopharmaceuticals Co Ltd  
Turn Biotechnologies Inc  
VasoDynamics Ltd  
Alopecia - Drug Profiles  
(cyclosporine A + minoxidil + RT-175) - Drug Profile  
Product Description  
Mechanism Of Action  
AB-101 - Drug Profile  
Product Description  
Mechanism Of Action  
AB-102 - Drug Profile  
Product Description  
Mechanism Of Action  
AB-103 - Drug Profile  
Product Description  
Mechanism Of Action  
AB-105 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
AD-106 - Drug Profile  
Product Description  
Mechanism Of Action  
AI-001 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
AKP-11 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
ANR-001 - Drug Profile  
Product Description  
Mechanism Of Action

**Antisense RNAi Oligonucleotides for Autoimmune Disorders - Drug Profile**

Product Description

Mechanism Of Action

**ARQ-255 - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**ATI-501 - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**baricitinib - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**BL-3000 - Drug Profile**

Product Description

Mechanism Of Action

**BMD-1141 - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**BQ-A - Drug Profile**

Product Description

Mechanism Of Action

**calcitriol - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**CB-0311 - Drug Profile**

Product Description

Mechanism Of Action

History of Events

**Cell Therapy for Alopecia - Drug Profile**

Product Description

Mechanism Of Action

**Cell Therapy for Coronavirus Disease 2019 (COVID-19), Alopecia Areata and Type 1****Diabetes - Drug Profile**

Product Description



Mechanism Of Action  
History of Events  
cerdulatinib - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CKD-843 - Drug Profile  
Product Description  
Mechanism Of Action  
CKHT-5108 - Drug Profile  
Product Description  
Mechanism Of Action  
crisaborole - Drug Profile  
Product Description  
Mechanism Of Action  
CS-12192 - Drug Profile  
Product Description  
Mechanism Of Action  
CS-12328 - Drug Profile  
Product Description  
Mechanism Of Action  
CU-40101 - Drug Profile  
Product Description  
Mechanism Of Action  
CWL-080061 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
daxdilimab - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
delgocitinib - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
deuruxolitinib phosphate - Drug Profile  
Product Description  
Mechanism Of Action

History of Events

DLQ-01 - Drug Profile

Product Description

Mechanism Of Action

Drug for Alopecia Areata - Drug Profile

Product Description

Mechanism Of Action

Drugs to Agonize Aryl Hydrocarbon Receptor for Alopecia, Vitiligo and Pemphigus -

Drug Profile

Product Description

Mechanism Of Action

dutasteride - Drug Profile

Product Description

Mechanism Of Action

History of Events

ENERGIF-701 - Drug Profile

Product Description

Mechanism Of Action

History of Events

EQ-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

etrasimod - Drug Profile

Product Description

Mechanism Of Action

History of Events

finasteride - Drug Profile

Product Description

Mechanism Of Action

History of Events

finasteride LA - Drug Profile

Product Description

Mechanism Of Action

History of Events

GT-20029 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Hair loss - Drug Profile  
Product Description  
Mechanism Of Action  
HC-0100 - Drug Profile  
Product Description  
Mechanism Of Action  
HC-017AA - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
HCW-9302 - Drug Profile  
Product Description  
Mechanism Of Action  
HMI-115 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
HS-301 - Drug Profile  
Product Description  
Mechanism Of Action  
HuABC-2 - Drug Profile  
Product Description  
Mechanism Of Action  
interferon beta-1b - Drug Profile  
Product Description  
Mechanism Of Action  
ivarmacitinib sulfate - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
jaktinib hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
KI-1104 - Drug Profile  
Product Description  
Mechanism Of Action  
KI-1105 - Drug Profile  
Product Description

Mechanism Of Action  
lithium gluconate - Drug Profile  
Product Description  
Mechanism Of Action  
LR-19030 - Drug Profile  
Product Description  
Mechanism Of Action  
Max-3 - Drug Profile  
Product Description  
Mechanism Of Action  
minoxidil - Drug Profile  
Product Description  
Mechanism Of Action  
minoxidil - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
MN-709 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
MTS-003 - Drug Profile  
Product Description  
Mechanism Of Action  
NG-13 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Oligonucleotide to Inhibit SFRP1 for Alopecia - Drug Profile  
Product Description  
Mechanism Of Action  
Oligonucleotides 1 for Androgenic Alopecia - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
OLX-104C - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events

OQL-071 - Drug Profile

Product Description

Mechanism Of Action

Peptide for Alopecia and Wounds - Drug Profile

Product Description

Mechanism Of Action

Personalized Hair Stem Cells - Drug Profile

Product Description

Mechanism Of Action

Protein to Antagonize PPAR Gamma-2 for Obesity, Alopecia, Osteoporosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

PT-002mn - Drug Profile

Product Description

Mechanism Of Action

PTN-103A - Drug Profile

Product Description

Mechanism Of Action

History of Events

PTN-103C - Drug Profile

Product Description

Mechanism Of Action

History of Events

pyrilutamide - Drug Profile

Product Description

Mechanism Of Action

History of Events

RCGD-423 - Drug Profile

Product Description

Mechanism Of Action

Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile

Product Description

Mechanism Of Action

ritlecitinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

rosnilimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Samcyprone - Drug Profile

Product Description

Mechanism Of Action

History of Events

SIS-023 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Cardiac Hypertrophy - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Alopecia - Drug Profile

Product Description

Mechanism Of Action

STS-01 - Drug Profile

Product Description

Mechanism Of Action

TAGX-0003 - Drug Profile

Product Description

Mechanism Of Action

TDM-105795 - Drug Profile

Product Description

Mechanism Of Action

History of Events

tesnatilimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

TH-07 - Drug Profile

Product Description

Mechanism Of Action

TRN-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

UK-5099 - Drug Profile

Product Description

Mechanism Of Action

Alopecia - Dormant Projects

Alopecia - Discontinued Products

Alopecia - Product Development Milestones

Featured News & Press Releases

Mar 26, 2022: Nearly 40% of adults with alopecia areata taking OLUMIANT 4-mg saw at least 80% scalp hair coverage at 52 weeks in Lilly's pivotal phase 3 studies

Mar 07, 2022: Kintor concludes enrolment of Phase II alopecia trial in China

Mar 06, 2022: Completion of patient enrollment in phase II clinical trial of KX-826 in China for the treatment of AGA in female patients

Mar 02, 2022: Kintor begins dosing Phase II androgenic alopecia treatment trial in US

Feb 04, 2022: Kintor doses first subject in US Phase I trial of dermatology asset

Feb 03, 2022: Kintor Pharmaceutical: Voluntary announcement first subject dosing in phase I clinical trial of GT20029 (ar-protac) in the United States

Jan 25, 2022: Hope Medicine announces US FDA clearance for phase II clinical trial of a first-in-class monoclonal antibody, HMI-115, in androgen alopecia

Jan 11, 2022: 3SBio announces submission and acceptance of the application for the market launch of 5% Minoxidil foam

Jan 04, 2022: Concert Pharmaceuticals completes enrollment in THRIVE-AA2 phase 3 clinical trial evaluating CTP-543 for Alopecia Areata

Jan 03, 2022: Kintor begins dosing in androgenic alopecia treatment trial in China

Nov 24, 2021: Kintor Pharma receives IND clearance by NMPA for KX-826's pivotal study to treat male alopecia patients

Nov 15, 2021: AnaptysBio announces positive rosnilimab healthy volunteer phase 1 top-line data

Nov 12, 2021: Kintor Pharma announces dosing of first patient in phase II clinical trial of KX-826 for the treatment of androgenic alopecia female patients in China

Oct 25, 2021: Concert Pharmaceuticals completes enrollment in THRIVE-AA1 phase 3 clinical trial evaluating CTP-543 for alopecia areata

Sep 30, 2021: OLUMIANT significantly improved hair regrowth to at least 80% scalp coverage as early as 24 weeks across first completed phase 3 studies for alopecia areata

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)

[Disclaimer](#)



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Alopecia, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Development by Companies, 2022 (Contd..2)  
Number of Products under Development by Companies, 2022 (Contd..3)  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Products under Development by Companies, 2022 (Contd..3)  
Products under Development by Companies, 2022 (Contd..4)  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Target, 2022 (Contd..1)  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Alopecia - Pipeline by 3SBio Inc, 2022  
Alopecia - Pipeline by Aclaris Therapeutics Inc, 2022  
Alopecia - Pipeline by Addpharma Inc, 2022  
Alopecia - Pipeline by Akaal Pharma Pty Ltd, 2022  
Alopecia - Pipeline by Alexion Pharmaceuticals Inc, 2022  
Alopecia - Pipeline by Almirall SA, 2022  
Alopecia - Pipeline by AnaptysBio Inc, 2022  
Alopecia - Pipeline by Aneira Pharma Inc, 2022  
Alopecia - Pipeline by AnToIRx Inc, 2022  
Alopecia - Pipeline by Applied Biology Inc, 2022  
Alopecia - Pipeline by Berg LLC, 2022  
Alopecia - Pipeline by Biolab Sanus Farmaceutica Ltda, 2022  
Alopecia - Pipeline by BiologicsMD Inc, 2022  
Alopecia - Pipeline by Bioquark Inc, 2022  
Alopecia - Pipeline by BirchBioMed Inc, 2022  
Alopecia - Pipeline by Caregen Co Ltd, 2022  
Alopecia - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022

Alopecia - Pipeline by CK Regeon Inc, 2022  
Alopecia - Pipeline by Concert Pharmaceuticals Inc, 2022  
Alopecia - Pipeline by Cosmo Pharmaceuticals NV, 2022  
Alopecia - Pipeline by DermalIQ Therapeutics Inc, 2022  
Alopecia - Pipeline by dNovo Inc, 2022  
Alopecia - Pipeline by Eli Lilly and Co, 2022  
Alopecia - Pipeline by Energenisis Biomedical Co Ltd, 2022  
Alopecia - Pipeline by Equillum Inc, 2022  
Alopecia - Pipeline by Exicure Inc, 2022  
Alopecia - Pipeline by Follica Inc, 2022  
Alopecia - Pipeline by Haplinscience Inc, 2022  
Alopecia - Pipeline by HCell Inc, 2022  
Alopecia - Pipeline by HCW Biologics Inc, 2022  
Alopecia - Pipeline by Hope Medicine Inc, 2022  
Alopecia - Pipeline by Horizon Therapeutics Plc, 2022  
Alopecia - Pipeline by Inventage Lab Inc, 2022  
Alopecia - Pipeline by Japan Tobacco Inc, 2022  
Alopecia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022  
Alopecia - Pipeline by JN Biosciences LLC, 2022  
Alopecia - Pipeline by Johnson & Johnson, 2022  
Alopecia - Pipeline by JW Pharmaceutical Corp, 2022  
Alopecia - Pipeline by Kedi Biomedical Co Ltd, 2022  
Alopecia - Pipeline by Kintor Pharmaceutical Ltd, 2022  
Alopecia - Pipeline by Kuhnle Pharmaceutical Co Ltd, 2022  
Alopecia - Pipeline by LG Chem Ltd, 2022  
Alopecia - Pipeline by Maxinovel Pharmaceuticals, 2022  
Alopecia - Pipeline by METiS Pharmaceuticals, 2022  
Alopecia - Pipeline by Mirae Cell Bio Co Ltd, 2022  
Alopecia - Pipeline by Nepsone ehf, 2022  
Alopecia - Pipeline by OliX Pharmaceuticals Inc, 2022  
Alopecia - Pipeline by Omega Therapeutics Inc, 2022  
Alopecia - Pipeline by OnQuality Pharmaceuticals LLC, 2022  
Alopecia - Pipeline by Pfizer Inc, 2022  
Alopecia - Pipeline by Phio Pharmaceuticals Corp, 2022  
Alopecia - Pipeline by Ponce Therapeutics Inc, 2022  
Alopecia - Pipeline by ProTransit Nanotherapy LLC, 2022  
Alopecia - Pipeline by RiverTown Therapeutics Inc, 2022  
Alopecia - Pipeline by Samson Clinical Pty Ltd, 2022  
Alopecia - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Alopecia - Pipeline by siRNAgen Therapeutics Corp, 2022  
Alopecia - Pipeline by Sisaf Ltd, 2022  
Alopecia - Pipeline by Soterios Ltd, 2022  
Alopecia - Pipeline by Stemson Therapeutics Corp, 2022  
Alopecia - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022  
Alopecia - Pipeline by TagCyx Biotechnologies, 2022  
Alopecia - Pipeline by Technoderma Medicines Inc, 2022  
Alopecia - Pipeline by Throne Biotechnologies Inc, 2022  
Alopecia - Pipeline by Tigo GmbH, 2022  
Alopecia - Pipeline by Triple Hair Inc, 2022  
Alopecia - Pipeline by Trittech Biopharmaceuticals Co Ltd, 2022  
Alopecia - Pipeline by Turn Biotechnologies Inc, 2022  
Alopecia - Pipeline by VasoDynamics Ltd, 2022  
Alopecia - Dormant Projects, 2022  
Alopecia - Dormant Projects, 2022 (Contd..1)  
Alopecia - Dormant Projects, 2022 (Contd..2)  
Alopecia - Dormant Projects, 2022 (Contd..3)  
Alopecia - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Alopecia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/AA8BCC7D1E5BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA8BCC7D1E5BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

